Acalabrutinib Shows Promise in CLL, Other Indications

Video

New data are being presented at ASH 2021 regarding the durable efficacy of acalabrutinib in chronic lymphocytic leukemia.

In an interview with Pharmacy Times, Niko Andre, MD, PhD, global franchise head of hematology and immuno-oncology at AstraZeneca, discussed the promising recent findings for acalabrutinib (Calquence; AstraZeneca) in the treatment of chronic lymphocytic leukemia (CLL).

In the interview, Andre said acalabrutinib is a next-generation Bruton's tyrosine kinase (BTK) inhibitor. He also discussed new data presented at the American Society of Hematology 2021 Annual Meeting, safety and adverse effects data for acalabrutinib, and how pharmacists can manage treatment with the drug.

Related Videos
lymphoma, OPC, ASCO 2024, hodgkin lymphoma
car t cell therapy multiple myeloma/Image Credit: © Lusi_mila - stock.adobe.com
Mid-section portrait of unrecognizable woman during last months of pregnancy holding her big belly gently standing against wall in blue room - Image credit: pressmaster | stock.adobe.com
palliative and hospice care/ Image Credits: © David Pereiras - stock.adobe.com
cancer pain management | Image Credits: © Burlingham - stock.adobe.com
multiple myeloma clinical trial daratumumab/ Image Credits: © Dragana Gordic - stock.adobe.com
multiple myeloma clinical trial/Image Credits: © Studio Romantic - stock.adobe.com
3d rendered illustration of lung cancer 3D illustration - Image credit:  appledesign | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.